Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: Results from phase 2/3 PURSUIT induction and maintenance studies

Journal of Crohn's and Colitis

Volumn 11, Issue 1, 2017, Pages 35-46

  Adedokun, Omoniyi J ^a   Xu, Zhenhua ^a   Marano, Colleen W ^a   Strauss, Richard ^a   Zhang, Hongyan ^a   Johanns, Jewel ^a   Zhou, Honghui ^a   Davis, Hugh M ^a   Reinisch, Walter ^b,f   Feagan, Brian G ^c   Rutgeerts, Paul ^d   Sandborn, William J ^e  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti tumour necrosis factor; Pharmacokinetics; Ulcerative colitis

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; DRUG ANTIBODY; GOLIMUMAB; IMMUNOMODULATING AGENT; SERUM ALBUMIN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; FECES ANALYSIS; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PANCOLITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SIDE EFFECT; STEADY STATE; ULCERATIVE COLITIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLITIS, ULCERATIVE; MIDDLE AGED; PATHOLOGY; REMISSION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85012997505     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw133     Document Type: Article

References (25)

1. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54
2. Murthy S, Kevans D, Seow CH, et al. Association of serum infliximab and antibodies to infliximab to long-term clinical outcome in acute ulcerative colitis. Gastroenterology 2012;142 [Suppl 1]:S-388
3. Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014;147:1296-307
4. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12:80-4
5. Paul S, Moreau AC, Del Tedesco E, et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis 2014;20:1288-95
6. Sandborn WJ, Feagan BG, Marano C, et al.; for the PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-95
7. Sandborn WJ, Feagan BG, Marano C, et al.; for the PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109
8. Detrez I, Dreesen E, VanStappen T, et al. Variability in golimumab exposure: a 'real-life' observational study in active ulcerative colitis. J Crohns Colitis 2016;10:575-81
9. Zhuang Y, Xu Z, Frederick B, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open label, randomised study. Clin Ther 2012;34:77-90
10. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. a randomised study. N Engl J Med 1987;317:1625-9
11. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86
12. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
13. Ternant D, Ducourau E, Perdriger A, et al. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol 2014;78:118-28
14. Xu Z, Davis HM, Zhou H. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. J Clin Pharmacol 2015;55 [Suppl 3]:S60-74
15. Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011;33:946-64
16. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009;65:1211-28
17. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014;63:1721-7
18. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54
19. Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis 2013;19:1112-22
20. Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol 2014;12:423-31
21. Marini J, Sendecki J, Cornillie F, et al. Comparison of commercially available assays for infliximab concentrations and antibodies to infliximab with assays developed at Janssen and used in clinical studies of Remicade® [infliximab] in IBD patients. United Eur Gastroenterol J 2015;3[5S]:A421
22. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919-27
23. Vande Casteele N, Gils A, Ballet V, et al. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT study. United Eur Gastroenterol J 2013;1[1S]:A1-A134
24. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 2014;20:1996-2003
25. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Gastroenterology 2013;144:S-92